PlayOn11 - Where Fans Become Winners
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2. S...

BUSINESS NEWS March 27, 2026

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2. Severe LAD-I is an ultra-rare, life-threatening pediatric...

12 views 0 likes 0 comments
First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2. Severe LAD-I is an ultra-rare, life-threatening pediatric...

Author: Business Wire

Read Original Article

Related News

Top Categories